Skip to main content
Selvita S.A. logo

Selvita S.A. — Investor Relations & Filings

Ticker · SLV ISIN · PLSLVCR00029 LEI · 25940057WQ9YP5MOQF28 WAR Professional, scientific and technical activities
Open in API
Filings indexed 1,179 across all filing types
Latest filing 2019-10-03 Major Shareholding Noti…
Country PL Poland
Listing WAR SLV

About Selvita S.A.

https://selvita.com/

Selvita S.A. is a preclinical contract research organization (CRO) providing integrated services for the pharmaceutical and biotechnology sectors. The company offers comprehensive solutions across the drug discovery and development continuum, from target validation to preclinical candidate nomination. Core drug discovery capabilities include medicinal chemistry, pharmacology, DMPK, and protein sciences, supporting a wide range of modalities such as small molecules, antibodies, and protein degraders. For drug development, Selvita provides analytical support for small and large molecules, formulation, microbiology services, and manufacturing for clinical trials. The company operates under GMP and GLP quality standards, offering flexible engagement models that range from standalone studies to fully integrated programs.

Recent filings

Filing Released Lang Actions
Informacja dotycząca rejestracji Akcji Podziałowych przez KDPW - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document is a formal announcement from the Management Board (Zarząd) of Selvita S.A. regarding the registration of new shares (11,921,229 Series B shares) in the Central Securities Depository of Poland (KDPW). This action is directly related to a corporate restructuring event (division of Ryvu Therapeutics S.A.). The content focuses on a change in the capital structure and the official registration of these new securities. This aligns best with the 'Capital/Financing Update' category, as it details the formalization of newly issued capital resulting from a corporate action, rather than just a general regulatory filing or a dividend announcement. The document is short and contains specific corporate action details, making CAP the most precise fit over the general RNS.
2019-10-03 Polish
Złożenie wniosku o dopuszczenie i wprowadzenie akcji podziałowych do obrotu na rynku regulowanym (podstawowym) GPW w ramach procesu podziału Ryvu Therapeutics S.A. oraz określenie Współczynnika Wyd...
Regulatory Filings Classification · 99% confidence The document is a formal announcement from the Management Board of Selvita S.A. (Emitent) regarding the submission of an application to the Warsaw Stock Exchange (GPW) for the admission and trading of 11,921,229 series B shares issued as part of a corporate spin-off (Podział) involving Ryvu Therapeutics S.A. (Spółka Dzielona). The text details the calculation and application of a 'Spin-off Ratio' (Współczynnik Wydzielenia) used to determine the opening reference prices for the shares of both resulting entities on the exchange. This content directly relates to changes in the company's capital structure and the listing of new shares following a corporate action (spin-off). This aligns best with the 'Capital/Financing Update' category (CAP), as it concerns the issuance of new shares and the resulting capital structure adjustments related to the spin-off process.
2019-10-03 Polish
Tekst jednolity statutu Selvita S.A.
Regulatory Filings Classification · 99% confidence The document text consists of detailed articles and paragraphs outlining the structure, purpose, capital, and governance bodies (General Meeting, Supervisory Board, Management Board) of a Polish joint-stock company ("STATUT SELVITA SPÓŁKA AKCYJNA"). This structure, including sections on capital structure (§ 7), shareholder rights (§ 8-12), and detailed rules for the General Meeting (§ 14-19) and Supervisory Board (§ 20-23), is characteristic of a company's Articles of Association or Charter (Statut). This document defines the fundamental rules of the company, which is distinct from periodic financial reports (10-K, IR) or meeting materials (AGM-R, DEF 14A). Since there is no specific code for 'Articles of Association' or 'Charter' among the provided options, and this document is foundational corporate governance information, the closest fit among the governance-related codes is 'Governance Information' (CGR), which covers internal rules and board structure.
2019-10-03 Polish
Rejestracja podwyższenia kapitału zakładowego Emitenta oraz zmiany statutu Emitenta dokonane w związku z Podziałem Ryvu Therapeutics S.A. (dawniej: Selvita S.A.) - Content (PL)
Share Issue/Capital Change Classification · 98% confidence The document text is a formal announcement from the management board ('Zarząd spółki Selvita S.A.') detailing significant changes to the company's charter (statute) following a capital increase resulting from a corporate spin-off ('podział przez wydzielenie'). Key elements include changes to the share capital amount, the number and type of shares (including voting rights), and the company name change. This directly relates to changes in the company's capital structure and corporate governance documents. The most fitting category is 'Capital/Financing Update' (CAP) as the core event is the capital increase registration and subsequent charter amendment. Although it involves governance changes, the primary trigger and focus is the capital structure adjustment. It is not a full 10-K, an ER, or a simple DIV announcement. The document is a formal notification of a structural change.
2019-10-03 Polish
Przystąpienie do systemu ESPI - Content (PL)
Report Publication Announcement Classification · 99% confidence The document text is very short (266 characters) and appears to be a formal announcement in Polish. The key phrase is "Spółka przystąpiła do systemu ESPI i z dniem 3 października 2019 r. rozpoczęła przekazywanie informacji bieżących i okresowych za pośrednictwem systemu ESPI." This translates to the company joining the ESPI system and starting to transmit current and periodic information through it as of October 3, 2019. This is a general administrative announcement regarding regulatory reporting channels, not a specific financial report (like 10-K, IR, ER) or a specific corporate action (like DIV, CAP, MANG). Since it is a general regulatory/administrative update that doesn't fit the highly specific categories, the most appropriate fallback is Regulatory Filings (RNS).
2019-10-03 Polish
Zatwierdzenie przez Sąd Rejestrowy podziału Emitenta oraz zmiana jego statutu - Content (PL)
Share Issue/Capital Change Classification · 99% confidence The document text details a corporate restructuring event involving a division (podział przez wydzielenie) of the company, a subsequent increase in share capital (podwyższenia kapitału zakładowego) through the issuance of new shares, and a change in the company's name (zmiana firmy). These actions directly relate to changes in the company's capital structure and corporate organization following a major transaction (spin-off/demerger). This aligns best with the 'Capital/Financing Update' category (CAP), as it explicitly discusses capital increase and structural changes resulting from the division, rather than just a simple share repurchase (POS) or a general announcement of a report (RPA/RNS).
2019-10-01 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.